Frontiers in Nuclear Medicine (May 2023)

Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients

  • Jan Taprogge,
  • Jan Taprogge,
  • Carla Abreu,
  • Carla Abreu,
  • Lenka Vávrová,
  • Lenka Vávrová,
  • Lily Carnegie-Peake,
  • Lily Carnegie-Peake,
  • Dominic Rushforth,
  • Dominic Rushforth,
  • Paul Gape,
  • Paul Gape,
  • Jonathan Gear,
  • Jonathan Gear,
  • Iain Murray,
  • Iain Murray,
  • Kee H. Wong,
  • Kate Newbold,
  • Siraj Yusuf,
  • Glenn Flux,
  • Glenn Flux

DOI
https://doi.org/10.3389/fnume.2023.964478
Journal volume & issue
Vol. 3

Abstract

Read online

IntroductionThe optimal strategy for differentiated thyroid cancer (DTC) patients treated with radioiodine (RAI) following thyroidectomy remains controversial. Multi-centre clinical studies are essential to identify strategies to improve patient outcomes while minimising treatment-induced toxicity.Materials and MethodsThe INSPIRE clinical trial (ClinicalTrials.gov Identifier: NCT04391244) aims to investigate patient-specific dosimetry for DTC patients and to determine the range of absorbed doses delivered to target and non-target tissues and their relationship with treatment outcome and toxicity.ResultsWe report here initial results of the first 30 patients enrolled onto the INSPIRE trial. A large range of absorbed doses are observed for both thyroid remnants and salivary glands, with median values of 4.8 Gy (Range 0.2 – 242 Gy) and 0.3 Gy (Range 0.1 to 1.7 Gy), respectively.DiscussionThe preliminary study results are encouraging and could help to improve our understanding of absorbed doses to thyroid remnants and normal organs following RAI therapy. Such knowledge could potentially enable patient-specific treatment planning with improved clinical outcomes and quality-of-life of patients.

Keywords